Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration

• Published in: Pharmacotherapy Vol. 31; no. 8; p. 729
• Main Authors: Zineh, Issam, Pacanowski, Michael A
• Format: Journal Article
• Language: English
• Published: United States 01.08.2011
• Subjects: Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations - metabolism; Pharmacogenetics; United States; United States Food and Drug Administration - organization & administration; United States
• ISSN: 1875-9114
• DOI: 10.1592/phco.31.8.729

Pharmacogenomics is the study of how genetic variations influence responses to drugs, diagnostics, or biologic agents. The field of pharmacogenomics has significant potential to enhance drug development and aid in making regulatory decisions. The United States Food and Drug Administration (FDA) has supported pharmacogenomics for nearly a decade by providing regulatory advice and reviewing applications, with the intent of discovering and applying genetic determinants of treatment effects. The FDA will continue to develop policies and processes centered on genomics and individualized therapeutics to guide rational drug development. It will also continue to inform the public of clinically relevant pharmacogenomic issues through various mechanisms of communication, such as drug labeling. In this review, we provide a perspective on several pharmacogenomic activities at the FDA. In addition, we attempt to clarify what we believe are several misperceptions regarding the FDA's pharmacogenomic initiatives. We hope this perspective provides a window into some ways in which the FDA is enabling individualized therapeutics through its mission-critical activities.